What is the 13F Pro Quality Score for ACRV?

13F Pro ranks Acrivon Therapeutics, Inc. (ACRV) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View ACRV's current score at https://13fpro.ai/research/ACRV (free sign-up required for the full ranking).

Where does 13F Pro source ACRV data?

All Acrivon Therapeutics, Inc. fundamentals and ownership data come directly from SEC EDGAR. Acrivon Therapeutics, Inc. files with the SEC under CIK 1781174. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is ACRV in?

Acrivon Therapeutics, Inc. (ACRV) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is ACRV research updated on 13F Pro?

ACRV's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Acrivon Therapeutics, Inc.(ACRV)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1781174 ACRV stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $0.0M in revenue.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

ACRV Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Acrivon Therapeutics, Inc. (ACRV), a Healthcare sector company. ACRV is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $0.0m in revenue. Based on the latest XBRL financial filings (Q1 2026), Acrivon Therapeutics, Inc. reports net income of $-19.0M, free cash flow of $-20.6M. Top institutional holders of ACRV by reported 13-F value include RA CAPITAL MANAGEMENT, L.P., Sands Capital Ventures,, WELLINGTON MANAGEMENT GROUP LLP, based on the most recent SEC filings. ACRV trades on the Nasdaq exchange and files with the SEC under CIK 1781174. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ACRV daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Acrivon Therapeutics, Inc. directly from SEC EDGAR.

Net Income

Q1 2026

$-19.0M

Free Cash Flow

Q1 2026

$-20.6M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Net Income

+3.3% YoY

$-77.9MFY 2025

FY22 $-31.2MFY23 $-60.4MFY24 $-80.6MFY25 $-77.9M

Operating Income

+5.7% YoY

$-84.1MFY 2025

FY22 $-32.7MFY23 $-67.1MFY24 $-89.2MFY25 $-84.1M

EPS (Diluted)

+15.1% YoY

$-2.02FY 2025

FY22 $-7.56FY23 $-2.74FY24 $-2.38FY25 $-2.02

Total Assets

-34.0% YoY

$129.7MFY 2025

FY22 $181.2MFY23 $138.3MFY24 $196.6MFY25 $129.7M

Op. Cash Flow

+3.1% YoY

$-63.7MFY 2025

FY22 $-30.1MFY23 $-42.6MFY24 $-65.7MFY25 $-63.7M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Net Income	$-77.9M +3.3%	$-80.6M -33.4%	$-60.4M -93.8%	$-31.2M -91.9%	$-16.2M
Operating Income	$-84.1M +5.7%	$-89.2M -32.9%	$-67.1M -105.5%	$-32.7M -101.8%	$-16.2M
EPS (Diluted)	$-2.02 +15.1%	$-2.38 +13.1%	$-2.74 +63.8%	$-7.56 +18.9%	$-9.32
Total Assets	$129.7M -34.0%	$196.6M +42.2%	$138.3M -23.7%	$181.2M +70.0%	$106.6M
Operating Cash Flow	$-63.7M +3.1%	$-65.7M -54.0%	$-42.6M -41.6%	$-30.1M -115.4%	$-14.0M

AI Insight: ACRV Financial Trends

Pre-revenue biotech burning cash at ~$20M quarterly while equity erodes 56% over two years; no commercial inflection visible.

• Net losses stabilized at $18–$23M/quarter through Q3 2025, then flattened at $19M in Q1 2026.

• Operating cash burn improved from $20M (Q1 2025) to $12M (Q3 2025), but deteriorated to $21M in Q1 2026.

• Equity declined 56% from $216M (Q2 2024) to $96M (Q1 2026) amid persistent operating losses and no revenue.

⚠ Operating CF worsened to $21M outflow in Q1 2026 after improving trend in H2 2025—signals deteriorating cash efficiency.

⚠ Equity runway reduced to ~5 quarters at current burn rate; no revenue or debt financing disclosed to extend runway.

AI Insight: ACRV Ratio Trends

Acrivon's returns have deteriorated sharply across all metrics, with Q1 2026 ROE at -79.7% and ROIC at -83.4%, marking the worst performance in the dataset.

• ROE collapsed from -34.8% in Q2 2024 to -79.7% in Q1 2026, a 44.9pp decline over nine quarters.

• ROIC declined from -39.7% in Q2 2024 to -83.4% in Q1 2026, worsening by 43.7pp despite no visible operational improvement.

• ROA deteriorated from -32.6% in Q2 2024 to -70.6% in Q1 2026, indicating severe asset inefficiency.

⚠ All return metrics have worsened sequentially from Q4 2025 to Q1 2026; no stabilization signal visible.

⚠ Consistently negative returns across 9 consecutive quarters suggest persistent losses without operational turnaround.

Get alerted when ACRV's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Acrivon Therapeutics, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of ACRV

RA CAPITAL MANAGEMENT, L.P.
$11.6M8,340,508 sh
Sands Capital Ventures, LLC
$3.0M2,122,605 sh
WELLINGTON MANAGEMENT GROUP LLP
$1.2M888,130 sh
RENAISSANCE TECHNOLOGIES LLC
$1.1M758,440 sh
VANGUARD CAPITAL MANAGEMENT LLC
$1.0M722,035 sh
MARSHALL WACE, LLP
$779.0K560,436 sh
TWO SIGMA INVESTMENTS, LP
$541.3K389,395 sh
JANE STREET GROUP, LLC
$333.2K239,691 sh
GEODE CAPITAL MANAGEMENT, LLC
$328.7K236,391 sh
BlackRock, Inc.
$290.4K208,939 sh

Fund	Value	Shares
RA CAPITAL MANAGEMENT, L.P.	$11.6M	8,340,508
Sands Capital Ventures, LLC	$3.0M	2,122,605
WELLINGTON MANAGEMENT GROUP LLP	$1.2M	888,130
RENAISSANCE TECHNOLOGIES LLC	$1.1M	758,440
VANGUARD CAPITAL MANAGEMENT LLC	$1.0M	722,035
MARSHALL WACE, LLP	$779.0K	560,436
TWO SIGMA INVESTMENTS, LP	$541.3K	389,395
JANE STREET GROUP, LLC	$333.2K	239,691
GEODE CAPITAL MANAGEMENT, LLC	$328.7K	236,391
BlackRock, Inc.	$290.4K	208,939

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put ACRV on your watchlist

Track score changes the day Acrivon Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is ACRV a good stock to buy?

13F Pro's AI-powered analysis of Acrivon Therapeutics, Inc. (ACRV) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ACRV are available on the ACRV stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own ACRV?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ACRV. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Acrivon Therapeutics, Inc.'s investment landscape.